JPY1,662.00
1.22% today
Tokyo, Oct 02, 06:16 am CET
ISIN
JP3336000009
Symbol
4536

Santen Pharmaceutical Target price 2025 - Analyst rating & recommendation

Santen Pharmaceutical Classifications & Recommendation:

Buy
77%
Hold
23%

Santen Pharmaceutical Price Target

Target Price JPY2,167.50
Price JPY1,642.00
Potential
Number of Estimates 10
10 Analysts have issued a price target Santen Pharmaceutical 2026 . The average Santen Pharmaceutical target price is JPY2,167.50. This is higher than the current stock price. The highest price target is
JPY2,730.00 66.26%
register free of charge
, the lowest is
JPY1,717.00 4.57%
register free of charge
.
A rating was issued by 13 analysts: 10 Analysts recommend Santen Pharmaceutical to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Santen Pharmaceutical stock has an average upside potential 2026 of . Most analysts recommend the Santen Pharmaceutical stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Billion JPY 300.00 296.94
0.65% 1.02%
EBITDA Margin 19.11% 21.02%
7.19% 10.02%
Net Margin 12.08% 11.87%
36.98% 1.76%

11 Analysts have issued a sales forecast Santen Pharmaceutical 2026 . The average Santen Pharmaceutical sales estimate is

JPY297b
Unlock
. This is
1.01% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
JPY323b 10.01%
Unlock
, the lowest is
JPY275b 6.49%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 JPY300b 0.65%
2026
JPY297b 1.02%
Unlock
2027
JPY306b 3.12%
Unlock
2028
JPY320b 4.39%
Unlock

11 Analysts have issued an Santen Pharmaceutical EBITDA forecast 2026. The average Santen Pharmaceutical EBITDA estimate is

JPY62.4b
Unlock
. This is
25.23% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
JPY72.6b 45.54%
Unlock
, the lowest is
JPY57.5b 15.39%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 JPY57.3b 7.79%
2026
JPY62.4b 8.92%
Unlock
2027
JPY66.9b 7.16%
Unlock
2028
JPY72.9b 8.89%
Unlock

EBITDA Margin

2025 19.11% 7.19%
2026
21.02% 10.02%
Unlock
2027
21.85% 3.95%
Unlock
2028
22.79% 4.30%
Unlock

11 Santen Pharmaceutical Analysts have issued a net profit forecast 2026. The average Santen Pharmaceutical net profit estimate is

JPY35.2b
Unlock
. This is
11.85% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
JPY44.4b 40.87%
Unlock
, the lowest is
JPY31.6b 0.39%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 JPY36.2b 36.09%
2026
JPY35.2b 2.80%
Unlock
2027
JPY39.9b 13.23%
Unlock
2028
JPY43.3b 8.59%
Unlock

Net Margin

2025 12.08% 36.98%
2026
11.87% 1.76%
Unlock
2027
13.03% 9.77%
Unlock
2028
13.55% 3.99%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share JPY 103.65 104.72
43.28% 1.03%
P/E 15.66
EV/Sales 1.78

11 Analysts have issued a Santen Pharmaceutical forecast for earnings per share. The average Santen Pharmaceutical EPS is

JPY104.72
Unlock
. This is
12.76% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
JPY131.88 42.00%
Unlock
, the lowest is
JPY93.98 1.20%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 JPY103.65 43.28%
2026
JPY104.72 1.03%
Unlock
2027
JPY118.57 13.23%
Unlock
2028
JPY128.75 8.59%
Unlock

P/E ratio

Current 17.65 26.43%
2026
15.66 11.29%
Unlock
2027
13.83 11.69%
Unlock
2028
12.73 7.95%
Unlock

Based on analysts' sales estimates for 2026, the Santen Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.80 11.33%
2026
1.78 0.91%
Unlock
2027
1.73 3.03%
Unlock
2028
1.66 4.20%
Unlock

P/S ratio

Current 1.89 11.53%
2026
1.87 1.00%
Unlock
2027
1.82 3.03%
Unlock
2028
1.74 4.21%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today